Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Celcuity LLC

CELC
Current price
14.89 USD +0.14 USD (+0.95%)
Last closed 14.61 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 522 655 392 USD
Yield for 12 month +32.36 %
1Y
3Y
5Y
10Y
15Y
CELC
21.11.2021 - 28.11.2021

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota. Address: 16305?36th Avenue North, Minneapolis, MN, United States, 55446

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

28.8 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

+229 648 USD

Current Year

-142 772 USD

Last Year

-210 918 USD

Current Quarter

-29 557 USD

Last Quarter

+201 700 USD

Key Figures CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -76 048 240 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -26.97 %
PEG Ratio
Return On Equity TTM -57.17 %
Wall Street Target Price 28.8 USD
Revenue TTM
Book Value 4.35 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -2.78 USD
Diluted Eps TTM -2.78 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics CELC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation CELC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -7.8025
Price Book MRQ 3.9081

Financials CELC

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators CELC

For 52 weeks

8.39 USD 22.19 USD
50 Day MA 16.41 USD
Shares Short Prior Month 1 875 171
200 Day MA 14.34 USD
Short Ratio 9.01
Shares Short 1 881 060
Short Percent 7.05 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

446.34 USD Microsoft Corporation -3.37 (-0.75%)
Detailed analytics

ETF funds


S

SLICHA

203.95 CHF UBS SLI A-dis -0.06 (-0.02%)
Detailed analytics

Metals


Gold

2339.94 USD Gold +11.09 (+0.48%)
Detailed analytics